<DOC>
	<DOCNO>NCT02635776</DOCNO>
	<brief_summary>The purpose study demonstrate efficacy safety AR101 reduction clinical reactivity peanut allergen peanut-allergic child adult .</brief_summary>
	<brief_title>Peanut Allergy Oral Immunotherapy Study AR101 Desensitization Children Adults ( PALISADE )</brief_title>
	<detailed_description>This international , multicenter , randomize , double-blind , placebo-controlled study efficacy safety AR101 characterize desensitization oral immunotherapy regimen peanut-allergic individual .</detailed_description>
	<mesh_term>Hypersensitivity</mesh_term>
	<mesh_term>Peanut Hypersensitivity</mesh_term>
	<criteria>Key Age 4 55 year Clinical history allergy peanut peanutcontaining food Serum immunoglobulin E ( IgE ) peanut ≥0.35 kUA/L ( kilos allergenspecific unit per liter , determine UniCAP™* within past 12 month ) and/or skin prick test ( SPT ) peanut ≥3 mm compare control Experience doselimiting symptom 100 mg challenge dose peanut protein ( measure 200 mg peanut flour ) Screening DBPCFC conduct accordance PRACTALL** guideline Not reside address another subject peanut OIT study UniCAP™* : laboratory system routine diagnostic test allergy tool basic study allergens antibody PRACTALL** : PRACTical issue ALLergology Joint United States/European Union Initiative Key History cardiovascular disease , include uncontrolled inadequately control hypertension History severe lifethreatening episode anaphylaxis anaphylactic shock within 60 day Screening DBPCFC History chronic disease ( asthma , atopic dermatitis , allergic rhinitis ) , significant risk become , unstable require change chronic therapeutic regimen History eosinophilic esophagitis ( EoE ) , eosinophilic gastrointestinal disease , chronic , recurrent , severe gastroesophageal reflux disease ( GERD ) , symptoms dysphagia recurrent gastrointestinal symptom undiagnosed etiology History mast cell disorder , include mastocytosis , urticarial pigmentosa , hereditary idiopathic angioedema Developing doselimiting symptom reaction placebo part Screening DBPCFC Having place residence another subject study</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>AR101 ( Characterized Peanut Allergen )</keyword>
	<keyword>Characterized Peanut Allergen</keyword>
	<keyword>CPNA ( Characterized Peanut Allergen )</keyword>
	<keyword>OIT ( oral immunotherapy )</keyword>
	<keyword>Oral Immunotherapy</keyword>
	<keyword>Peanut Allergy</keyword>
	<keyword>Allergy</keyword>
	<keyword>Peanut-Allergic Children</keyword>
	<keyword>Peanut-Allergic Adults</keyword>
	<keyword>Desensitization</keyword>
</DOC>